Nicolas Girard
#151,609
Most Influential Person Now
Researcher ORCID ID = 0000-0001-9909-2299
Nicolas Girard's AcademicInfluence.com Rankings
Nicolas Girardcomputer-science Degrees
Computer Science
#8024
World Rank
#8443
Historical Rank
Data Science
#176
World Rank
#179
Historical Rank
Computational Linguistics
#1717
World Rank
#1735
Historical Rank
Machine Learning
#3168
World Rank
#3207
Historical Rank
Nicolas Girardmathematics Degrees
Mathematics
#7013
World Rank
#9615
Historical Rank
Measure Theory
#1792
World Rank
#2196
Historical Rank
Download Badge
Computer Science Mathematics
Nicolas Girard's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Nicolas Girard Influential?
(Suggest an Edit or Addition)Nicolas Girard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Immune Landscape of Cancer (2018) (2766)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- New driver mutations in non-small-cell lung cancer. (2011) (1085)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. (2015) (386)
- Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (296)
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients (2017) (268)
- Deep learning-based classification of mesothelioma improves prediction of patient outcome (2019) (257)
- ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting (2014) (217)
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas (2015) (217)
- The Integrated Genomic Landscape of Thymic Epithelial Tumors. (2018) (210)
- Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. (2006) (210)
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. (2018) (205)
- The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
- Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 (2014) (195)
- Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases (2009) (194)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Thymoma associated with autoimmune diseases: 85 cases and literature review. (2016) (185)
- Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. (2009) (176)
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study (2021) (168)
- PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. (2019) (163)
- Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas (2009) (162)
- The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
- Thymoma: a focus on current therapeutic management. (2009) (151)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma (2013) (144)
- Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers (2009) (137)
- Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy (2018) (132)
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. (2018) (130)
- Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. (2014) (114)
- Comparisons of microRNA Patterns in Plasma before and after Tumor Removal Reveal New Biomarkers of Lung Squamous Cell Carcinoma (2013) (112)
- Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. (2016) (109)
- Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids (2019) (99)
- EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. (2020) (97)
- Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. (2009) (94)
- From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF) (2012) (91)
- Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? (2018) (91)
- Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma (2011) (87)
- Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report (2010) (86)
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
- The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
- 3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells (2014) (73)
- High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. (2015) (73)
- Jaagsiekte Sheep Retrovirus (JSRV): from virus to lung cancer in sheep. (2007) (72)
- A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics (2019) (70)
- Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. (2010) (69)
- Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. (2010) (68)
- Is the treatment of hepatocellular carcinoma on the waiting list necessary? (2011) (66)
- Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice (2009) (65)
- Chemotherapy definitions and policies for thymic malignancies. (2011) (64)
- Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. (2006) (64)
- Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. (2018) (63)
- New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center (2018) (58)
- Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. (2019) (56)
- Thymic Tumors: Relevant Molecular Data in the Clinic (2010) (54)
- Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients (2014) (54)
- Regulation and Role of TGFβ Signaling Pathway in Aging and Osteoarthritis Joints. (2014) (53)
- Standard-fractionated radiotherapy for optic nerve sheath meningioma: visual outcome is predicted by mean eye dose. (2012) (52)
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). (2020) (51)
- Systemic treatments for thymoma and thymic carcinoma: A systematic review. (2018) (49)
- Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. (2019) (49)
- Chemotherapy and targeted agents for thymic malignancies (2012) (48)
- Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2018) (48)
- Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies (2010) (47)
- Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. (2005) (47)
- Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer (2021) (46)
- New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts (2020) (46)
- State of the Art of Genetic Alterations in Thymic Epithelial Tumors (2014) (44)
- Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. (2006) (43)
- MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung (2017) (43)
- Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. (2016) (42)
- A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. (2019) (41)
- Infections opportunistes et sarcoïdose (2004) (40)
- Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions (2019) (40)
- Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series (2017) (39)
- Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. (2018) (37)
- Thymic epithelial tumours: from basic principles to individualised treatment strategies (2013) (37)
- Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome (2018) (35)
- c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas (2018) (34)
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (32)
- Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center. (2020) (32)
- OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2017) (32)
- Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors (2017) (32)
- Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma. (2017) (32)
- Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units (2014) (29)
- The Distribution of Mediastinal Lesions across Multi-Institutional, International, Radiology Databases. (2019) (28)
- Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors (2017) (28)
- Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature (2017) (28)
- A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER (2020) (27)
- Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). (2014) (27)
- EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. (2019) (27)
- [Opportunistic infections and sarcoidosis]. (2004) (26)
- The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors (2020) (26)
- Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2017) (25)
- Type II TGFβ receptor modulates chondrocyte phenotype (2013) (25)
- Immune reconstitution inflammatory syndrome mimicking relapsing cryptococcal meningitis in a renal transplant recipient (2011) (24)
- Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab (2020) (24)
- OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer (2021) (23)
- A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. (2018) (23)
- Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. (2006) (23)
- Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1 (2019) (23)
- Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. (2010) (22)
- A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas database study. (2019) (22)
- FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer (2020) (22)
- Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. (2019) (22)
- The role of radiotherapy in the management of thymic tumors. (2011) (21)
- Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study. (2019) (21)
- Neuroendocrine tumors of the thymus: the oncologist point of view. (2017) (20)
- Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients (2021) (19)
- FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets (2021) (18)
- Regulatory mechanism of transforming growth factor beta receptor type II degradation by interleukin-1 in primary chondrocytes. (2012) (18)
- Optimal management of thymic malignancies: current perspectives (2019) (18)
- Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis (2018) (18)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
- P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC (2018) (17)
- Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. (2018) (17)
- Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer. (2009) (17)
- Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas (2017) (16)
- Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). (2014) (16)
- Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. (2019) (16)
- Novel Agents in the Treatment of Thymic Malignancies (2017) (15)
- Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma. (2018) (15)
- Respiratory failure with diffuse bronchiectases and cryoglobulinaemia (2008) (15)
- [Chemotherapy definitions and policies for thymic malignancies]. (2014) (15)
- Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. (2018) (14)
- Assessing the Multimodal Management of Advanced Solitary Fibrous Tumors of the Pleura in a Routine Practice Setting (2015) (14)
- Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. (2021) (14)
- Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas (2018) (14)
- Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. (2015) (13)
- 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) (13)
- Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature (2019) (13)
- Proposals for managing patients with thoracic malignancies during COVID-19 pandemic (2020) (13)
- First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN (2020) (12)
- Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France. (2013) (12)
- Thymic Epithelial Tumor‐Associated Cytopenia: A 10‐Year Observational Study in France (2016) (12)
- Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice. (2020) (12)
- Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. (2021) (12)
- LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial (2021) (12)
- Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. (2017) (12)
- 1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP) (2017) (11)
- Histone methylases as novel drug targets: developing inhibitors of EZH2. (2014) (11)
- Lymphoma, Lymphoproliferative Diseases, and Other Primary Malignant Tumors (2010) (11)
- PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. (2021) (11)
- Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors (2020) (11)
- Cytoreductive Pleurectomy and Intrathoracic Chemohyperthermia for Pleural Relapse of Thymomas. (2019) (11)
- Systemic treatment for thymic malignancies (2016) (11)
- UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). (2021) (11)
- Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. (2022) (11)
- [Sorafenib and radiotherapy association for hepatocellular carcinoma]. (2011) (11)
- Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). (2021) (10)
- Pulmonary artery sarcoma, a paradigm of orphan thoracic oncology. (2009) (10)
- [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. (2018) (10)
- European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review (2021) (10)
- Radiotherapy for locally advanced non-small cell lung cancer. (2009) (10)
- ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? (2015) (10)
- The IASLC Thymic Tumors Staging Project. The Impact of the 8th Edition of the UICC/AJCC TNM Stage Classification of Thymic Tumors: Results of a Survey. (2019) (9)
- PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. (2019) (9)
- Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study (2021) (9)
- 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) (9)
- Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study (2011) (9)
- A Focus on Current Therapeutic Management (2009) (9)
- Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. (2022) (9)
- MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients (2019) (9)
- Oligometastases for Clinicians: Size Matters. (2021) (8)
- Thymic malignancies: Twisting between autoimmunity and immunotherapy. (2017) (8)
- [Stereotactic radiotherapy for non-small cell lung cancer: From concept to clinical reality. 2011 update]. (2011) (8)
- Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial (2021) (8)
- Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients (2020) (8)
- MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations (2021) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study (2021) (8)
- Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database. (2017) (8)
- [Rythmic-pathology: the French national pathology network for thymic epithelial tumours]. (2014) (8)
- Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines (2020) (8)
- Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). (2022) (7)
- Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma (2021) (7)
- [Tolerance and efficacy of conformal radiotherapy for hepatocellular carcinoma in cirrhotic patients. Results of the French RTF1 phase II trial]. (2005) (7)
- [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review]. (2008) (7)
- Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study (2014) (7)
- Targeted therapies for thymic malignancies. (2011) (7)
- Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. (2022) (7)
- Rapid detection of EGFR mutations in decalcified lung cancer bone metastasis (2020) (7)
- Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening. (2021) (7)
- Blocked expression of key genes of the angiogenic pathway in JSRV-induced pulmonary adenocarcinomas (2017) (7)
- Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. (2022) (6)
- Anti-inflammatory effects of an injectable copolymer of fatty acids (Ara 3000 beta®) in joint diseases (2015) (6)
- Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer. (2018) (6)
- Thymic tumours: an update. (2013) (6)
- Immune checkpoints in thymic epithelial tumors: challenges and opportunities (2019) (6)
- LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) (2021) (6)
- Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. (2016) (6)
- [Lung cancer: epidemiology and screening]. (2017) (6)
- Other signalization targets (2013) (6)
- Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722) (2019) (6)
- Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survival. (2020) (6)
- Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers (2022) (6)
- Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature. (2021) (6)
- RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection. (2021) (6)
- A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes (2021) (6)
- Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI) (2019) (5)
- MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC (2018) (5)
- CARMN‐NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract (2021) (5)
- Crizotinib in ALK-positive lung cancer. (2012) (5)
- Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? (2016) (5)
- The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas. (2019) (5)
- Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board. (2021) (5)
- How large databases may impact clinical practices for rare tumors-postoperative chemotherapy in thymic malignancies. (2016) (5)
- Retroperitoneal fibrosis: a rare vascular and immune entity disclosed by chronic lombalgia. (2007) (5)
- IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC. (2017) (5)
- Thymic Carcinomas - A Concise Multidisciplinary Update on Recent Developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. (2022) (4)
- [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]. (2012) (4)
- OA 16.03 Recurrences and 2nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery (2017) (4)
- Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience. (2019) (4)
- First real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU) (2019) (4)
- [Recommendations of French specialists on screening for lung cancer]. (2021) (4)
- Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF) (2022) (4)
- Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymomas. (2017) (4)
- Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers (2020) (4)
- Clinical Applications of Kinase Inhibitors in Solid Tumors (2010) (4)
- Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy. (2021) (4)
- Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
- [Thymoma and autoimmune diseases]. (2018) (4)
- Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience. (2016) (4)
- Thymic Tumors: Revisiting Autoimmunity to Give a Chance to Immunotherapy. (2018) (4)
- Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. (2020) (4)
- Lymph Node Dissection in Thymoma: Is it worth it? (2021) (3)
- Topics in thoracic oncology: from surgical resection to molecular dissection (2013) (3)
- Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. (2020) (3)
- Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC (2020) (3)
- Pathological central review of 400 thymic epithelial tumors (TET): The national network RYTHMIC experience (2016) (3)
- 533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours (2020) (3)
- P2.04-006 Updated Incidence of Thymic Epithelial Tumors (TET) in France and Clinical Presentation at Diagnosis: Topic: Thymic Malignancies Clinical and Translational (2017) (3)
- Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. (2022) (3)
- Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study (2022) (3)
- Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network. (2020) (3)
- Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center (2021) (3)
- Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort. (2020) (3)
- 1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) (2020) (3)
- Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival (2021) (3)
- Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report (2022) (3)
- High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC (2021) (3)
- New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer (2022) (3)
- Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. (2021) (3)
- Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. (2022) (3)
- Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates (2019) (2)
- Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study (2022) (2)
- Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial (2022) (2)
- Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC. (2020) (2)
- Thymic tumours and their special features (2021) (2)
- Treatment options for stage IVA thymic malignancies (2019) (2)
- MA04.01 Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network (2021) (2)
- Thymic malignancies: emerging systemic therapies. (2019) (2)
- Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System. (2017) (2)
- [Gemcitabine and radiotherapy for the future]. (2007) (2)
- 54 – Rare Primary Lung Tumors (2016) (2)
- OA 03.01 Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC (2017) (2)
- Second‐Line Treatment Selection in Patients With Non–Small‐Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians (2017) (2)
- Reply to "Better Prognostic Models May Result in Improved Patient Selection for Adjuvant Therapies After Complete Resection of Solitary Fibrous Tumors of the Pleura". (2015) (2)
- Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease (2018) (2)
- [Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. (2020) (2)
- Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors. (2021) (2)
- A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer (2022) (2)
- 1P Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion (2021) (2)
- Case presentation and recommendations from the April 2019 ITMIG tumor board: an international multidisciplinary team (2019) (2)
- 3023 Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network (2015) (2)
- 1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) (2021) (2)
- Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG). (2011) (2)
- Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective (2013) (2)
- The IASLC Thymic Epithelial Tumors Staging Project: unresolved issues to be addressed for the next 9th edition of the TNM classification of malignant tumors. (2022) (2)
- [Chemoradiation for locally advanced non-small cell lung cancer]. (2007) (2)
- PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors (2021) (2)
- Strategies of Lymph Node Dissection During Sublobar Resection for Early-Stage Lung Cancer (2021) (2)
- Thymic tumors: adopting an orphan thoracic tumor as a model of personalized medicine. (2014) (2)
- Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report. (2009) (2)
- From the old to the new: The EURACAN Project (2018) (2)
- [Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!]. (2007) (2)
- [Radiotherapy for non-small cell lung cancer]. (2009) (2)
- SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. (2020) (2)
- Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study (2022) (2)
- Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer (2023) (2)
- [Quality criteria of thoracic radiotherapy. Application to clinical research]. (2007) (1)
- [Pulmonary metastases from malignant meningioma]. (2010) (1)
- [Screening studies of lung cancer: implications for monitoring of pulmonary nodules]. (2012) (1)
- P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1: Topic: Phase III (2017) (1)
- Clubbing, Arthralgia and a Large Intrathoracic Mass (2012) (1)
- [French experience of gefitinib in non-small cell bronchial carcinoma]. (2004) (1)
- Highlights of the 2nd European Lung Cancer Conference (2010) (1)
- AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC (2017) (1)
- Proton Beam Therapy for Thymic Carcinoma with Pericardial Involvement (2020) (1)
- Use of immune checkpoint inhibitors in thymic epithelial tumors (2018) (1)
- Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours (2019) (1)
- P1.06-005 An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted: Topic: Advanced General (2017) (1)
- Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC. (2021) (1)
- Cardiovascular effects of innovative therapies in lung cancer (2020) (1)
- Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma (2012) (1)
- Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma (2018) (1)
- 53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC (2020) (1)
- Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry (2022) (1)
- [NSCLC and new oncogenic mutations: Diagnosis and perspectives]. (2021) (1)
- Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply. (2022) (1)
- Disentangling heterogeneity of Malignant Pleural Mesothelioma through deep integrative omics analyses (2021) (1)
- International expert consensus on immunotherapy for early-stage non-small cell lung cancer (2022) (1)
- 56 – Thymic Tumors (2018) (1)
- [A case of mediastinal angiosarcoma]. (2012) (1)
- [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. (2020) (1)
- Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient (2021) (1)
- Loco-Regional Control and Survival Outcomes After Combined Stereotactic Radiation Therapy and Immune Checkpoint Inhibitors for Brain Metastases From Non-Small Cell Lung Cancer. (2021) (1)
- Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung (2022) (1)
- Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care. (2021) (1)
- [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]. (2021) (1)
- Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases (2022) (1)
- [Lung cancer screening: physicians open up dialogue]. (2012) (1)
- [Therapeutic strategies in superior sulcus tumors: a model for combined modality therapy in non-small cell lung cancer]. (2007) (1)
- Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis (2019) (1)
- EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022 (2022) (1)
- MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions (2019) (1)
- Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study. (2018) (1)
- 1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection (2021) (1)
- Optimal delineation of the clinical target volume for thymomas in the post-resection setting: a multi-center study. (2021) (1)
- Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study (2014) (1)
- [Confidentiality in medical practice: tell no one]. (2009) (1)
- P3.02c-032 Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients: Topic: IT (2017) (1)
- An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (2023) (1)
- Clinical practices for non-neoplastic thymic lesions: Results from a multidisciplinary cohort. (2022) (1)
- Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience (2021) (1)
- [Stage IIIB non-small cell lung cancer. Optimization of radiotherapy in lung cancer: some interesting questions to be solved]. (2006) (1)
- 823: 3-deazaneplanocin A (DZNep), an inhibitor of histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells (2014) (1)
- [Stereotactic radiotherapy and radiofrequency ablation for early-stage lung cancer]. (2012) (1)
- P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study: Topic: EGFR Clinical (2017) (1)
- Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer (2023) (1)
- [External radiotherapy for hepatocellular carcinoma]. (2011) (1)
- Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors? (2019) (1)
- Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. (2022) (1)
- 1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study (2020) (1)
- Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. (2022) (1)
- Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes (2020) (1)
- Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. (2021) (1)
- EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors. (2022) (1)
- Are sarcomatoid lung cancers resistant tumors to conventional chemotherapy (2013) (0)
- AB004. Optimal delineation of the clinical target volume for thymomas in the postoperative setting: a multi-center study (2021) (0)
- Bone and metabolic parameters are associated with overall survival in patients with bone metastases from adenocarcinoma lung cancer: the POUMOS study (2016) (0)
- P84.06 Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study (2021) (0)
- Extra-cost of brain metastases in patients with non-squamous non-small cell lung cancer (NSCLC): A French national hospital database analysis. (2018) (0)
- Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies. (2018) (0)
- Oral 1.02. Sunitinib in patients with advanced thymic epithelial tumors (TET) (2015) (0)
- [Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française]. (2014) (0)
- 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes (2021) (0)
- [Opacities and intra-thoracic masses]. (2008) (0)
- OC-0628 Regional Control after Stereotactic Radiation therapy and Immunotherapy for NSCLC Brain Metastases (2021) (0)
- Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database. (2019) (0)
- In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50. (2023) (0)
- Treatment and outcome of a patient with radiation-induced organizing pneumonia in the context of coronavirus disease 2019 (COVID-19) (2021) (0)
- From Cancer Mimicking Orphan Lung Disease to Orphan Thoracic Oncology (2015) (0)
- Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2020) (0)
- LUNG CANCER AND COMBINED PULMONARY FIBROSIS AND EMPHYSEMA SYNDROME IN WESTERN PATIENTS: A SERIES OF 47 PATIENTS (2013) (0)
- ORAL1.01: PHASE II TRIAL OF AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED THYMIC MALIG- NANCIES (2015) (0)
- Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort (2019) (0)
- P3-9-64Hadrontherapy by carbon ions, an innovative approach to treat chondrosarcomas (2015) (0)
- 1371P Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): results from an EORTC pan-European survey. (2017) (0)
- Second‐line treatment selection in patients with non‐small cell lung cancer of adenocarcinoma histology: A European survey: 183P (2016) (0)
- [Treatment of stage III non-small lung carcinomas: is there controversy?]. (2006) (0)
- National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France. (2014) (0)
- P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors (2021) (0)
- 52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study (2020) (0)
- Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients) (2020) (0)
- P2.04-003 Chemotherapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study (2021) (0)
- [Thymic tumors]. (2017) (0)
- Transsternal transpericardial closure of a postpneumonectomy bronchial fistula in a patient who underwent pneumonectomy because of a war injury (2009) (0)
- GGO and minimally invasive adenocarcinomas: how to deal with? (2018) (0)
- 110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France (2021) (0)
- [Lung cancer: 10 points to remember]. (2017) (0)
- PCN102 - EXTRA-COST OF BRAIN METASTASES IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) : A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS (2018) (0)
- 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer (2021) (0)
- Iconography : IMAGERIE DE LA NEUROFIBROMATOSE DE TYPE 2 (2008) (0)
- 102P IMreal Cohort 2: First interim analysis of patient (pt) characteristics and safety data in pts with locally advanced or metastatic NSCLC (aNSCLC) receiving atezolizumab (atezo) under real-world conditions (2021) (0)
- EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study. (2021) (0)
- Radiation Therapy in Thymoma (2018) (0)
- Iconographies supplémentaires de l'article : Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer (2009) (0)
- [Mucosa-associated lymphoid tissue-derived (MALT) lymphoma]. (2016) (0)
- Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies? (2019) (0)
- Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients. (2019) (0)
- Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy (2023) (0)
- AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network (2017) (0)
- [A difficult diagnosis]. (2009) (0)
- Lymphome de type Mucosa-Associated Lymphoid Tissue , (MALT) pulmonaire, puis gastrique (2016) (0)
- 924: Comparative study of chondrosarcomas response to DNA damage: Impact of HIF2 expression (2014) (0)
- Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice (2021) (0)
- Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. (2021) (0)
- Réarrangements de ALK, diagnostic, traitement, perspectives (2014) (0)
- MA02.03 The Evolution of Lung Neuroendocrine Tumors (2022) (0)
- 47P Central nervous-system (CNS) metastases in thymic epithelial tumours (TET): Real-world insight from RYTHMIC (2021) (0)
- P25.01 Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study (2021) (0)
- Case presentations and recommendations from the 2018 ITMIG Annual Meeting (2020) (0)
- PUB054 Pathological Discrepancies in the Diagnosis of Thymic Malignancies: The Tallinn-Lyon Experience (2017) (0)
- P2.04-005 WHO Classification and IASLC/ITMIG Staging Proposal in Thymic Tumors: Real-Life Assessment: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. (2022) (0)
- [Early-stage NSCLC. The renaissance of radiotherapy in early-stage non-small cell lung cancer]. (2008) (0)
- Bronchiolite lymphocytaire clonale B isolée : diagnostic par analyse de réarrangement génique (2013) (0)
- [Surgery and chemoradiation in stage IIIA non-small cell lung cancer]. (2006) (0)
- [Pulmonary diffusion test to NO and CO time course during thoracic radiotherapy for lung cancer: the CONORT prospective study protocol]. (2014) (0)
- MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey (2019) (0)
- Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in non-small cell lung cancer patients (2020) (0)
- OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients (2022) (0)
- [Drug Approval: Tepotinib - advanced relapse MET exon-14 in non-small-cell lung cancers]. (2022) (0)
- PCN17 Health-Related Quality of Life (HRQOL) of ALK-Rearranged NON-SMALL CELL LUNG Cancer (NSCLC) Patients Treated in Second LINE with Alectinib (2020) (0)
- AB008. Activated pathways of Thymic Epithelial Tumors: a RYTHMIC study (2022) (0)
- Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy (2023) (0)
- GR01.04 Medical Oncology (2018) (0)
- Response to Letter to the Editor From Binghao Zhao et al. (2023) (0)
- Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity (2023) (0)
- Abstract 45: Screening somatic genomic alteration for rare adult cancers: the SPECTA-ARCAGEN project of the EORTC/EURACAN (2022) (0)
- [Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use]. (2022) (0)
- Thymic tumors: impact of the TNM for medical oncologists: extended abstract (2022) (0)
- OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients (2022) (0)
- Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1 (2019) (0)
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
- Prospective Radiologic-Pathologic Correlation of Macroscopic Volume and Microscopic Extension of Nonsolid Lung Nodules on Thin-section CT Images for Sublobar Resection and Stereotactic Radiotherapy Planning. (2022) (0)
- Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies (2022) (0)
- [Establishing at a shared and common educational assessment at Curie Institute]. (2021) (0)
- Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816 (2023) (0)
- Brief Report on Teleconsultation in Lung Cancer: Toward a Semiotic Paradigm Shift? (2022) (0)
- Patient Perspectives on Value Dimensions of Lung Cancer Care: Cross-sectional Web-Based Survey (2022) (0)
- 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort (2020) (0)
- Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies (2021) (0)
- Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report. (2022) (0)
- Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. (2022) (0)
- Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs (2018) (0)
- [Pulmonary metastatic angiosarcoma]. (2009) (0)
- A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation (2020) (0)
- [Radiotherapy and targeted therapies in non-small-cell lung cancer]. (2009) (0)
- [Concurrent chemoradiation in lung cancer]. (2005) (0)
- OA09.03 MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach (2021) (0)
- Epigenetic therapy: a treatment for chondrosarcoma ? (2014) (0)
- Clinical Presentation and Diagnosis of Thymic Neoplasms (2018) (0)
- Quality of resection and outcome in stage III thymic epithelial tumors (TET): A retrospective analysis of 150 cases from the national network RYTHMIC experience (2016) (0)
- ["Fortuitous discovery of a thymoma"]. (2021) (0)
- Recurrent and metastatic carcinomas of the lacrimal gland: High frequency of ERBB2 driven disease. (2018) (0)
- Thymoma: from chemotherapy to targeted therapy. (2012) (0)
- Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study (2023) (0)
- [ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]. (2014) (0)
- 532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours (2021) (0)
- Immune-related endocrine toxicities in non-small cell lung cancer: predictors of outcome to checkpoint inhibitors? (2019) (0)
- 3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours (2015) (0)
- FDG PET/CT is more efficient than bone scintigraphy in detecting bone metastases in patients with newly diagnosed advanced lung cancer: the POUMOS-Image Study (2015) (0)
- Molecular Targetable Pathways – EGFR (2021) (0)
- Epigenetic therapy; a promising treatment for chondrosarcoma? (2014) (0)
- Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104]. (2016) (0)
- An overview: ongoing systemic therapy trials in thymic epithelial tumors around the world-will anything “hit”? (2021) (0)
- Pseudo-tumours and reciprocal mimics of neoplastic and non-neoplastic pulmonary disorders (2011) (0)
- Iconography : Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report (2009) (0)
- Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer (2019) (0)
- AB026. LA11. Thymic malignancies tumor board: medical oncology (2018) (0)
- [A difficult end of life]. (2009) (0)
- ED15.02 Chemotherapy and Targeted Therapies of Thymic Malignancies (2017) (0)
- Reply to "better prognostic models may result in improved patient selection for adjuvant therapies after complete resection of solitary fibrous tumors of the pleura". (2015) (0)
- Ocular and Orbital Tumors: Viewpoint-Fractionated Radiation (2015) (0)
- OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications (2019) (0)
- P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC (2021) (0)
- 421PDProspective monitoring of lung function tests with CO and NO diffusion during high dose thoracic radiotherapy for lung cancer: The CONORT study (2015) (0)
- Exploratory analyses of surrogate endpoints in metastatic non-small cell lung cancer (2021) (0)
- Subtotal Pleurectomy with Intrathoracic Chemo Hyperthermia (HITHOC) for IVa Thymomas: De Novo Versus Recurrent Pleural Disease (2022) (0)
- Use of an Internet-based protocol to collect clinical information and blood from patients with lung cancer who never smoked cigarettes. (2009) (0)
- [Periarteritis nodosa disclosed by epilepsy in a drug addict with hepatitis B and C virus carrier state]. (1997) (0)
- [Neoadjuvant chemoradiation in non-small cell lung cancer]. (2007) (0)
- Molecular characterization of commonly used chondrosarcoma cell lines (2015) (0)
- FP05.04 Outcomes of Resected Thymic Epithelial Tumors (TET), insights from RYTHMIC (2021) (0)
- [How should we deal with law in oncology]. (2009) (0)
- Driver mutations as predictive biomarkers in lung cancer (2012) (0)
- Epidemiology of Thymic Neoplasms (2018) (0)
- Biology of Human Tumors Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers : A Proof-of-Concept Study (2014) (0)
- Is There a Role for Postoperative Radiotherapy in Elderly Patients with Early-Stage Non-small Cell Lung Cancer? (2013) (0)
- 3538 POSTER Phase I study of concurrent chemoradiation including twice-weekly low dose gemcitabine for unresectable pancreatic adenocarcinoma (2007) (0)
- Plasma-derived cfDNA to reveal potential biomarkers of response prediction and monitoring in non-small cell lung cancer (NSCLC) patients on immunotherapy. (2020) (0)
- 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) (0)
- N2 Nodal Involvement in Multiple Primary Lung Cancer: Response (2013) (0)
- MTP14-01: Fraction, volume dose in radiation therapy (2007) (0)
- [Chemoradiation therapy: a model for treatment optimization in oncology]. (2006) (0)
- EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents. (2022) (0)
- Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets (2022) (0)
- [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No]. (2015) (0)
- Unusual Bilateral Acinar Nodules: Case for Diagnosis (2009) (0)
- OA18.07 Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience (2017) (0)
- [The role of neoadjuvant chemoradiation in pancreatic cancer]. (2006) (0)
- Small-Cell Cancer of the Lung: Pathology and Genetics (2018) (0)
- OA18.01 Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort (2017) (0)
- Efficacy of weekly paclitaxel-bevacizumab combination in advanced nonsquamous non-small cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. (2021) (0)
- Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy. (2022) (0)
- Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial. (2021) (0)
- Comparative study of the sensibility of chondrosarcoma to DNA damaging agents (2014) (0)
- A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicolas Girard?
Nicolas Girard is affiliated with the following schools:
